Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.
暂无分享,去创建一个
D. Nam | I. Nakano | J. Rich | Cheolju Lee | Y. Shin | Jeongwu Lee | K. Joo | Eunhee Kim | Mi-Suk Kim | D. Woo | Nakho Chang | Young-Taek Oh | Jihye Shin | Jingeun Rheey | Hong‐Gyum Kim | Dong-Hun Woo
[1] H. Woo,et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. , 2013, Cell reports.
[2] M. Loda,et al. EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.
[3] P. Atadja,et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.
[4] D. Noh,et al. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. , 2012, Molecular cell.
[5] Tim J. Wigle,et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.
[6] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[7] Guang-Yuh Chiou,et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis , 2012, Journal of cellular physiology.
[8] Qiang Yu,et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.
[9] L. D. Croce,et al. Roles of the Polycomb group proteins in stem cells and cancer , 2011, Cell Death and Disease.
[10] Erika Pastrana,et al. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. , 2011, Cell stem cell.
[11] R. McLendon,et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. , 2011, Cancer cell.
[12] G. Stark,et al. Lysine methylation of promoter-bound transcription factors and relevance to cancer , 2011, Cell Research.
[13] D. Reinberg,et al. The Polycomb complex PRC2 and its mark in life , 2011, Nature.
[14] G. Stark,et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes , 2010, Proceedings of the National Academy of Sciences.
[15] P. Dirks,et al. Brain tumor stem cells: The cancer stem cell hypothesis writ large , 2010, Molecular oncology.
[16] E. Hurt,et al. Clinical significance of Polycomb gene expression in brain tumors , 2010, Molecular Cancer.
[17] M. Wolter,et al. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas , 2010, International journal of cancer.
[18] K. Helin,et al. Polycomb group protein-mediated repression of transcription. , 2010, Trends in biochemical sciences.
[19] Yonghong Xiao,et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. , 2010, Cancer cell.
[20] Jane Fridlyand,et al. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. , 2010, Cancer research.
[21] G. Stark,et al. Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65 , 2009, Proceedings of the National Academy of Sciences.
[22] Wei Keat Lim,et al. The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.
[23] Nicolò Riggi,et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. , 2009, Cancer research.
[24] A. Ross,et al. Cancer stem cells: Cell culture, markers, and targets for new therapies , 2009, Journal of cellular biochemistry.
[25] Guido Nikkhah,et al. NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts , 2009, Stem cells.
[26] B. Cochran,et al. STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells , 2009, Stem cells.
[27] Robert E. Kingston,et al. Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.
[28] Justin C. Grindley,et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.
[29] G. Bernier,et al. BMI1 Sustains Human Glioblastoma Multiforme Stem Cell Renewal , 2009, The Journal of Neuroscience.
[30] Mark Bernstein,et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. , 2009, Cell stem cell.
[31] H. Fine,et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.
[32] Fang Liu,et al. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. , 2009, Cancer research.
[33] P. Yue,et al. Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.
[34] J. Simon,et al. Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.
[35] Gordon B Mills,et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.
[36] G. Stark,et al. Roles of unphosphorylated STATs in signaling , 2008, Cell Research.
[37] Yuri Kotliarov,et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. , 2008, Cancer cell.
[38] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[39] T. Mikkelsen,et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.
[40] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[41] D. Frank. STAT3 as a central mediator of neoplastic cellular transformation. , 2007, Cancer letters.
[42] Qiang Yu,et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.
[43] M. Fraga,et al. The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.
[44] Zohar Yakhini,et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer , 2007, Nature Genetics.
[45] P. Laird,et al. Epigenetic stem cell signature in cancer , 2007, Nature Genetics.
[46] G. Broggi,et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.
[47] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[48] Anke Sparmann,et al. Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.
[49] S. Berger,et al. Repression of p53 activity by Smyd2-mediated methylation , 2006, Nature.
[50] J. Zeitlinger,et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells , 2006, Nature.
[51] William A Weiss,et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.
[52] Yuri Kotliarov,et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.
[53] Megan F. Cole,et al. Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.
[54] M. Hung,et al. Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.
[55] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[56] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[57] Ugo Orfanelli,et al. Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.
[58] Daniel H. Geschwind,et al. Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[59] Debashis Ghosh,et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[60] D. Reinberg,et al. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.
[61] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[62] Hengbin Wang,et al. Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.
[63] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[64] R. Kingston,et al. Stabilization of Chromatin Structure by PRC1, a Polycomb Complex , 1999, Cell.
[65] S. Akira,et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.
[66] J. Darnell,et al. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.
[67] Tzong-Shiue Yu,et al. A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .
[68] S. Orkin,et al. PRC2 directly methylates GATA4 and represses its transcriptional activity. , 2012, Genes & development.
[69] W. Weiss,et al. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. , 2010, Current topics in microbiology and immunology.
[70] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[71] J. Uhm,et al. The transcriptional network for mesenchymal transformation of brain tumours , 2010 .
[72] R. McLendon,et al. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. , 2010, Genes & cancer.
[73] Yuan Qi,et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .
[74] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[75] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .
[76] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[77] Zang Ai-hua,et al. Stem Cells,Cancer and Cancer Stem Cells , 2005 .